Novartis Ag (NVS) EBITDA (2009 - 2025)

Novartis Ag (NVS) has 15 years of EBITDA data on file, last reported at $17.7 billion in Q2 2025.

• Quarterly EBITDA rose 340.53% year-over-year to $17.7 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $56.6 billion (down 98.87% YoY) and the FY2025 annual result came in at $17.6 billion, up 21.31% from the prior year.
• EBITDA declined to $17.7 billion in Q2 2025 per NVS's latest filing, from $29.4 billion in the prior quarter.
• The five-year high for EBITDA was $34000.7 billion in Q1 2022, with the low at -$999.2 billion in Q4 2022.
• Average EBITDA over 5 years is $2792.5 billion, with a median of $10.4 billion recorded in 2022.
• The widest YoY moves for EBITDA: up 4657533.01% in 2022, down 121658.27% in 2022.
• Novartis Ag's EBITDA stood at $822.0 million in 2021, then sank by 121658.27% to -$999.2 billion in 2022, then soared by 100.54% to $5.4 billion in 2023, then soared by 442.71% to $29.4 billion in 2024, then plunged by 39.94% to $17.7 billion in 2025.
• Business Quant data shows NVS's EBITDA at $17.7 billion in Q2 2025, $29.4 billion in Q4 2024, and $4.0 billion in Q2 2024.